Introduction

Factors to Consider When Selecting a BTK

Inhibitor for a Patient With CLL
Covalent BTK Inhibitors in CLL
Combination Therapies and Noncovalent
BTK Inhibitors
Patient Case 1
Patient Case 1 (cont)
Treatment Selection for Untreated Patients With CLL With TP53
Mutation
Expert Discussion
Treatment Selection for Untreated Patients With CLL With TP53
Mutation
Expert Discussion
Treatment Selection for Untreated Patients With CLL With TP53
Mutation
Expert Discussion
Treatment Selection for Untreated Patients With CLL With TP53
Mutation
Expert Discussion
Treatment Selection for Untreated Patients With CLL With TP53
Mutation
Expert Discussion
Patient Case 1 (cont)
Discussion With Patients Before Starting Treatment With BTK
Inhibitors
Expert Discussion
Patient Case 1 (cont)
Patient Case 2
Treatment Selection for Untreated Patients With CLL With
Hypertension
Expert Discussion
Treatment Selection for Untreated Patients With CLL With
Hypertension
Expert Discussion
Patient Case 2 (cont)
Patient Case 2 (cont)
Managing AEs of BTK Inhibitors: Atrial
Fibrillation
Expert Discussion
Patient Case 2 (cont)
Patient Case 3
How to Approach Intolerance to a BTK
inhibitor?
Expert Discussion
Patient Case 3 (cont)
Patient Case 3 (cont)
Progression on a BTK inhibitor
Expert Discussion
Progression on a BTK inhibitor
Expert Discussion
Pirtobrutinib in Previously Treated CLL/SLL
Phase 1/2 BRUIN: Adverse Events
Nemtabrutinib in CLL/SLL
Phase 2 BELLWAVE-001: Adverse Events
Future Options for CLL Treatment
Expert Discussion